

**Supplementary Table 6. Associations between inflammatory markers and predictors of mortality or disease severity.** Inflammatory marker risk groups tested for association with known predictors of mortality from or development of severe Covid-19 for the whole dataset ( $n=1,071$ ).  $P$  values shown for strength of association determined via Pearson's chi-square test.

Inflammatory Marker	# of Comorbidities (0/1/2+, %)	$P$ Value	# of Complications (0/1/2+, %)	$P$ Value	Anti-cancer Therapy at Diagnosis (N/Y %)	$P$ Value	Sex (F/M, %)	$P$ value	Age (65/ $\geq 65$ , %)	$P$ value
<b>NLR</b>										
NLR6	133/147/230 (26.1%/28.8%/45.1%)	<b>.0001</b>	191/176/111 (40.0%/36.8%/23.2%)	<b>.0001</b>	216/274 (44.1%/55.9%)	<b>.001</b>	243/264 (47.9%/52.1%)	<b>.0001</b>	235/274 (46.2%/53.8%)	<b>.0001</b>
NLR $\geq 6$	86/141/299 (16.3%/26.8%/56.8%)		117/205/165 (24.0%/42.1%/33.9%)		282/228 (55.3%/44.7%)		187/339 (35.6%/64.4%)		172/350 (33.0%/67.0%)	
<b>PLR</b>										
PLR270	109/150/230 (22.3%/30.7%/47.0%)	0.064	163/177/115 (35.8%/38.9%/25.3%)	<b>0.020</b>	236/246 (49.0%/51.0%)	0.747	214/273 (43.9%/56.1%)	0.212	202/282 (41.7%, 58.3%)	0.069
PLR $\geq 270$	99/125/267 (20.2%/25.5%/54.4%)		134/183/152 (28.6%/39.0%/32.4%)		243/243 (50.0%/50.0%)		196/294 (40.0%/60.0%)		177/314 (36.0%/64.0%)	
<b>OIS</b>										
OIS40	69/76/124 (25.7%/28.3%/46.1%)	<b>0.010</b>	104/102/46 (41.3%/40.5%/18.3%)	<b>.0001</b>	127/129 (49.6%/50.4%)	0.124	115/154 (42.8%/57.2%)	0.152	115/154 (42.8%/57.2%)	<b>0.049</b>
OIS $\leq 40$	71/91/222 (18.5%/23.7%/57.8%)		88/130/134 (25.0%/36.9%/38.1%)		205/162 (55.9%/44.1%)		142/240 (37.2%/62.8%)		135/249 (35.2%/64.8%)	
<b>mGPS</b>										
0	50/53/66 (29.6%/31.4%/39.1%)	<b>.001</b>	73/62/26 (45.3%/38.5%/16.1%)	<b>.0001</b>	75/91 (45.2%/54.8%)	<b>0.005</b>	82/87 (48.5%/51.5%)	<b>0.036</b>	85/84 (50.3%/49.7%)	<b>0.004</b>
1	52/49/95 (26.5%/25.0%/48.5%)		58/85/39 (31.9%/46.7%/21.4%)		99/91 (52.1%/47.9%)		80/116 (40.8%/59.2%)		79/117 (40.3%/59.7%)	
2	52/73/182 (16.9%/23.8%/59.3%)		64/98/118 (22.9%/35.0%/42.1%)		178/116 (60.5%/39.5%)		111/194 (36.4%/63.6%)		106/201 (34.5%/65.5%)	
<b>PI</b>										
0	45/43/54 (31.7%/30.3%/38.0%)	<b>0.002</b>	62/54/20 (45.6%/39.7%/14.7%)	<b>.0001</b>	59/80 (42.4%/57.6%)	<b>.0001</b>	70/72 (49.3%/50.7%)	<b>0.139</b>	73/69 (51.4%/48.6%)	<b>0.001</b>
1	102/149/295 (18.7%/27.3%/54.0%)		126/209/170 (25.0%/41.4%/33.7%)		245/282 (46.5%/53.5%)		218/326 (40.1%/59.9%)		209/332 (38.6%/61.4%)	
2	24/43/73 (17.1%/30.7%/52.1%)		26/54/51 (19.8%/41.2%/38.9%)		94/40 (70.1%/29.9%)		58/82 (41.4%/58.6%)		43/97 (30.7%/69.3%)	

N: No; Y: Yes; F: Female; M: Male; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; OIS: OnCovid Inflammatory Score; mGPS: Modified Glasgow prognostic score; PI: Prognostic index